Six patients (21\p=n-\50 years) with growth hormone deficiency and panhypopituitarism were given recombinant growth hormone, somatropin, 0.04\p=n-\0.1 U\m=.\kg\m=.\body wt-1\m=.\ day-1, for 12 months. All patients reported improved well-being with increased working capacity. Bone (2, 3, 5, 11) . However, no improvement of the low bone mineral density could be demonstrated after three months of GH treatment (10).
Growth hormone therapy in GH-deficient children has been a reality for may years, but such therapy has generally been withdrawn after puberty and achieve¬ ment of the final height. In healthy subjects, however, GH secretion continues after linear growth has ceased, although the amount of secreted hormone decreases with increasing age (1) .
GH has both anabolic and lipolytic actions, and the consequences of many years of GH deficiency during adult life are, thus far, inadequately evaluated. GHdeficient adults have been shown to have increased fat volume and decreased muscle volume (2, 3) as well as decreased lean body mass (4, 5) . Bone mineral density has also been shown to be lower than in normal agematched subjects (6, 7) . Several factors could influence the low bone mass in these patients. A normal peak bone mass is not reached until several years after puberty and achievement of final height, and this means that the GHdeficient patients are left without GH substitution during a period very important for attaining normal peak bone mass. In patients with several pituitary hormone defi¬ ciencies, the difficulties optimizing the induction of puberty and substitution with gonadal steroids, as well as the risk of oversubstitution with cortisone and thyroxine, also make the patients with hypopituitarism extraordinarily disposed to developing osteopenia. The frequency of fractures in older adults with panhypopituitarism is not known, but it appears likely that low bone mineral density may constitute a risk factor for bone fragility and fractures in later life. In addition, adults with panhypopituitarism and adequate thyroxine, corti¬ sone and gonadal steroid substitution therapy, have been shown to have a low quality of life (8) and a decreased life expectancy (9) .
The availability of recombinant GH has now made it possible to evaluate the effect of GH substitution therapy with adults having GH deficiency. Recent studies have shown that GH treatment for three to six months in GHdeficient adults improved general well-being (10) and influenced body composition and lean body mass, resulting in increased muscle mass and decreased adi¬ pose tissue (2, 3, 5, 11) . However, no improvement of the low bone mineral density could be demonstrated after three months of GH treatment (10) . 3.7 MBq (100 yd) of 3H20 (Amersham) was given orally (14) . After (20) . It is possible that a GH induced increase of bone mass in GHdeficient adults is most rapidly induced in trabecular bone and therefore is detected earlier in lumbar ver¬ tebrae than in the distal forearm. In this context it must be noted that the GH doses (0.28-0.70 U-kg-1'week1)
given in the present study induced an increase of IGF-1 to levels above the mean of healthy subjects aged 20- (25) . In addition, IGF-2 is the major skeletal growth factor found in human bone (26) , and the concentration of GH independent IGF-2 is more than tenfold higher than that of IGF-1 in rat bone conditioned medium (27) . Therefore, it is difficult to attribute the GH effect to only the paracrine action of bone-derived IGF-1. Endocrine IGF-1 may also mediate the GH effect on bone in humans or GH could regulate some bone derived IGF binding proteins, which subse¬ quently modulate the action of paracrine IGF-2.
The patients participating in this study reported improved well-being and improved physical capacity during the treatment period. Apart from initial fluid retention and artralgia in some patients, no adverse effects were encountered. Fasting blood glucose levels increased during treatment, but remained within the normal range in all patients during treatment.
In conclusion, the beneficial effects of GH therapy in adults with panhypopituitarism favour substitution therapy being considered in all ages in these patients. With regard to the substantial improvement of bone mineral density, the effects of GH treatment during other conditions involving osteopenia should be evaluated.
